5. (Amended). After " according" change "to any one of claims 1 to 4" to --claim 4--.

6. (Amended). After " according" change "to any one of claims 1 to 5" to --claim 5--.

7. (Amended). After " according" change "to any one of claims 1 to 6" to --claim 6--.

9. (Amended). The method according to claim 8, wherein said VH-chain [comprises one of the two sequences shown in Fig. 7 (nucleotides 1 to 381)and Fig. 8 (nucleotides 1 to 339)] is selected from the group consisting of nucleotides 1 to 381 of Seq. ID NO: 143 and nucleotides 1 to 339 of Seq. ID No.: 145 and [/or] said VL chain [comprises one of the two sequences shown in Fig 6(nucleotides 1 to 321) and Fig 9 (nucleotides 1 to 321)] is selected from the group consisting of nucleotides 1 to 321 of Seq. ID No.: 141 and nucleotides 1 to 321 of Seq. ID No.: 147.

10. (Amended). After " according" change "to any one of claims 1 to 9" to --claim 9--.

11. (Amended). After " according" change "to any one of claims 1 to 10" to --claim 10--.

13. (Amended). After " according" change "to any one of claims 1 to 12" to --claim 12--.

14. (Amended). After " according" change "to any one of claims 1 to 13" to --claim 13--.

16. (Amended). After " according" change "to any one of claims 1 to 13" to --claim 15--.

17. (Amended). After " according" change "to any one of claims 1 to 16" to --claim 16--.

18. (Amended). An anti-human antigen receptor obtained by the method according to claim 1, said anti-human antigen receptor being [that is] low or not immunogenic in humans, and [comprises] comprising a combination of functionally rearranged VH and VL chains wherein at least said VH chain is derived from essentially unprimed mature human B-lymphocytes [or from essentially anergic human B-cells and obtainable by the method according any one of claims 1 to17] and said VL chain is derived from a naturally occurring human B cell repertoire.

20. (Amended). The anti-human antigen receptor according to claim [18 or 19 which is] 19, said anti-human antigen receptor being specific for a human tumor antigen.

21. (Amended). The anti-human antigen receptor according to claim [20 which is]22, said anti-human antigen receptor being specific for the native human 17-1A antigen.

22. (Amended). The anti-human antigen receptor according to claim [21] 18 wherein said VH [comprises one of the two sequences shown in Fig. 7 (nucleotides 1 to 381)and Fig. 8 (nucleotides 1 to 339)] is selected from the group consisting of nucleotides 1 to 3381 of Seq. ID NO: 143 and nucleotides 1 to 339 of Seq. ID No.: 145 and [/or] said VL chain [comprises one of the two sequences shown in Fig 6(nucleotides 1 to 321) and Fig 9 (nucleotides 1 to 321)] is selected from the group consisting of nucleotides 1 to 321 of Seq. ID No.: 141 and nucleotides 1 to 321 of Seq. ID No.: 147.

26. (Amended). A kit comprising a combination of functionally rearranged VH and VL immunoglobulin chains wherein at least one of the VH and VL chains [are] is derived from essentially unprimed mature human B-lymphocytes, [or from essentially anergic B-cells,] said chains being expressible from recombinant vectors of an in vitro display system.

28. (Amended). An [antibody] anti-human antigen receptor obtained by the method according to claim17, said [antibody] anti-human antigen being characterized in that it is derived from human sequences, and is specific for the native human 17-1A antigen.

29. (Amended). Delete "antibody" and replace it with --anti-human antigen receptor-- After "claim 28" change "which is" to --said anti-human antigen receptor being--.

31. (Amended). Delete "antibody" and replace it with --anti-human antigen receptor-- and change "any one of claims 28 to 30" to--claim 29--.

32. (Amended). Delete "antibody" and replace it with --anti-human antigen receptor-- and change "any one of claims 28 to 31" to--claim 31--.

Please add the following new claims:

--34. (New). The anti-human antigen receptor according to claim 22, said anti-human antigen receptor comprising a VH chain or at least one CDR.

--35. (New). The anti-human antigen receptor according to claim 34 wherein said CDR is CDR3.

--36. (New). The anti-human antigen receptor according to claim 22, said receptor comprising a VL chain or at least one CDR--.

--37. (New). The anti-human antigen receptor according to claim 36 wherein said CDR is CDR3--.

--38. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier--.

--39. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 19, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier--.

--40. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 20, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier--.

--41. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 21, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier--.

--42. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 22, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier--.

--43. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18 comprising at least one CDR and a pharmaceutically acceptable carrier--.

--44. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 19 comprising at least one CDR and a pharmaceutically acceptable carrier--.

--45. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 20 comprising at least one CDR and a pharmaceutically acceptable carrier--.

--46. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 21 comprising at least one CDR and a pharmaceutically acceptable carrier--.